The French Ministry of Health and Social Affairs. This randomized control trial investigated glucose control with closed-loop (CL) versus threshold-low-glucose-suspend (TLGS) insulin pump delivery in pre-pubertal children with type 1 diabetes in supervised hotel conditions. The patients [n = 24, age range: 7-12, HbA1c: 7.5 AE 0.5% (58 AE 5 mmol/mol)] and their parents were admitted twice at a 3-week interval. CL control to range or TLGS set at 3.9 mmoL/L were assessed for 48 hour in randomized order.
| INTRODUCTION
Glucose control remains a challenge in children with type 1 diabetes (T1D) as shown by the trend for no reduction of HbA1c level with frequent severe hypoglycaemia in the 6 to 12 age group in the T1D Exchange clinical registry. 1 Commercially available sensor-augmented pump therapy (SAP) with automated stopping of insulin infusion when continuous glucose monitoring (CGM) reaches a predefined glucose threshold [thresholdlow-glucose-suspend (TLGS)] has shown significant reduction of time in hypoglycaemia. 2, 3 Investigational control-to-range (CTR) algorithms, used in closed-loop (CL) control systems, also designated as artificial pancreas (AP), have also shown a reduction of the occurrence of hypoglycaemia at night and significantly improved glycaemic control when compared to SAP in adults in outpatient clinical trials. [4] [5] [6] Recent AP investigations in children have been reported in diabetic camp studies showing variable results on the reduction of hypoglycaemia and average glucose level under AP vs. SAP. [7] [8] [9] Because AP systems are more complex and may be more difficult to manage in a child population, our objective was to assess in prepubertal children with T1D
the outcomes of a system with CTR algorithm-driven insulin delivery against a TLGS-equipped system on glucose control with a primary focus on nocturnal hypoglycaemia, safety and perception by users and their relatives.
| MATERIALS AND METHODS

| Study design
The study is a randomized control trial preceded by a run-in period and follows a cross-over design ( Figure S1 , panel A). The study protocol was approved by the Comité de Protection des Personnes SudMéditerranée III, Nîmes, France, and registered in ClinicalTrails.gov under number NCT02509429.
After a 3-week run-in period allowing familiarization with the study CGM, the patients and their parents were admitted to hotels for two 3-day sessions ( Figure S1 , panel B) at 3-week intervals. After a first night in standard pump therapy mode dedicated to checking the safety of device connections, either CL using a CTR algorithm or a TLGS mode with a 3.9 mmoL/L threshold were activated for 48 h according to randomization. Meal boluses were managed based upon individual insulin/carb. Ratio for the three meals and the afternoon snack, with no food limitation.
| Subjects
Twenty-four prepubertal patients (stage 1 of Tanner Classification), 7 to 12 years old, T1D diagnosis >1 year, insulin pump therapy >6 months, with HbA1c <8.5% were recruited after patients and parents signed informed consent/assent.
| Study devices
The study insulin pump was the t:AP system (Tandem Diabetes Care, San Diego, CA) infusing the patient's usual fast-acting insulin analog.
The study CGM was the Dexcom G4 sensor with AP Share receiver (Dexcom, San Diego, CA In addition, DiAs allowed for secured data streaming over the internet to a remote monitoring website using the smart-phone 3G
connection. The patients were remotely monitored at all times by the study team to enable assisting the patient in the case of device issues, and patients/parents were trained to follow the glycaemic safety guidelines (see the Safety Protocols in the supporting information for this article).
| Outcomes
The primary outcome was the % CGM time <3.9 mmoL/L over the second and third nights of the sessions. The secondary outcomes included the % CGM time <3.9 mmoL/L over 48 hour, as well as the % CGM time in the 3.9 to 10.0 mmoL/L and 3.9 to 7.8 mmoL/L ranges, <2.8, >10.0 and 13.9 mmoL/L, and the mean sensor glucose level, overnight and over 48 hour. The impact of the experience with the AP mode was assessed in the patients by the Artificial Pancreas Acceptance 12 and the Hypo Fear Survey 13 questionnaires, the latter one also being completed by the parent(s), prior to randomization and after the second study session. The usability of the CL system was assessed by the frequency of needed interventions on pump, CGM and DiAs due to malfunctions.
| Statistical methods
Based on clinical results of the TLGS and the UVA CL systems, the effect size on the primary outcome (Cohen's D coefficient) was estimated to be 0.7; assuming a power of 0.9 (90%) and a significance threshold of 0.05, the necessary sample size was 24.
Data analysis was based on the intention-to-treat principle. All glucose data corresponded to CGM data. We reported variables as median (25th and 75th percentiles) for non-normally distributed data and as mean AE SD otherwise. Default analysis was performed via paired Student t-test for difference in the mean, while non-normally distributed variables were analysed using Wilcoxon paired sign rank test. All Pvalues are two-sided and <0.05 was considered statistically significant.
| RESULTS
The main characteristics of the 24 patients at inclusion are presented in Table S1 .
Twenty-three patients completed the full study and contributed to study analyses, since one patient failed in performing the CTRalgorithm session due to a software problem. Table 1 shows the results of the primary and secondary glucose outcomes overnight (22:00-08:00) and over the 48-hour sessions. 
| AP acceptance questionnaire
Median (25th, 75th percentiles) score was 76 (71, 85) before and 82 (76, 87) after the trial, indicating a significantly improved AP acceptance (P = 0.041). These scores correspond to 84% and 91% of maximal score, i.e. a very good acceptance of the AP technology by the patients.
| Fear of hypo questionnaires
Children's median (25th, 75th percentiles) overall scores were 33 (21, 44) and 31 (23, 41) before and after the study (P = 0.629).
Behaviour and worry scores were 16 (11, 20) and 12 (9, 25), respectively, before, and 16 (13, 21; P = 0.146) and 13 (9, 19; P = 0.629), respectively, after the study. The median scores at the end of the study represented 25%, 27% and 18% of maximal overall, behaviour and worry scores, respectively, i.e. rather low fear of hypoglycaemia. 
| Usability of the CL system
The rates of interventions for malfunctions were 0. under SAP to 2% under CL. 7 However, % CGM time <3.9 mmoL/L was much lower under SAP: 1.6% in, 9 and under TLGS: 3.1% in our study. This observation points to the still difficult tuning of CL algorithms according to patients. In patients who are more prone to hypoglycaemia, the choice of a less aggressive algorithm to prevent hypoglycaemic excursions exposes them to a lower % time in the target range, such as in, 7 whereas tighter control can be aimed at patients showing less of a trend towards hypoglycaemia, such as in. 9 The high acceptance score of the CL system in spite of technical issues has also been reported elsewhere. 14 Beside improved glucose sensors for a better detection of hypoglycaemia, the size, the visibility and cumbersome wear of the system have been identified as significant worries of parents whose children participated in CL trials. 15 The limitations of our study include its short duration in a still highly supervised environment. Longer studies in true free-living conditions are needed for a deeper assessment of the technological options whose feasibility of use has nevertheless been demonstrated in children. Moreover, Predictive LGS, which was not commercially available when we initiated the study, will now be a more appropriate comparator to CL than TLGS.
In conclusion, our study demonstrates a similar effectiveness of a SAP with TLGS and a CL system using a CTR algorithm on the nighttime spent in hypoglycaemia in prepubertal T1D patients in a supervised setting of short duration. However, CL allows for tighter glucose control. Embedment of the CL algorithm in the pump and improved glucose sensor accuracy should increase the benefits of CL for T1D children.
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